Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569671 | 1.00 | OPRL1 (0.44) | OPRL1CTRB1TSHRHTTFASN | |
| SCHEMBL10420330 | 1.00 | OPRL1 (0.44) | OPRL1CTRB1TSHRHTTFASN | |
| SCHEMBL7838610 | 1.00 | OPRL1 (0.44) | OPRL1CTRB1TSHRHTTFASN | |
| SCHEMBL6875994 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL740389 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL740390 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL740391 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL13172946 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL13534719 | 0.85 | OPRL1 (0.42) | OPRL1CTRB1FASN | |
| SCHEMBL10510512 | 0.84 | CYP2D6 (0.47) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307184-B2 | Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds | KANEKA CORPORATION (JP) | 2007-12-11 | — | — | US | claimed |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | KANEKA CORPORATION (JP) | 2004-09-16 | — | — | US | claimed |
| EP-1403257-A1 | PROCESSES FOR PRODUCING OXAZOLIDINONE DERIVATIVE OF BETA-HYDROXYETHYLAMINE COMPOUND AND FOR PRODUCING BETA-HYDROXYETHYLAMINE COMPOUND | KANEKA CORPORATION (JP) | 2004-03-31 | — | — | EP | claimed |
| CN-1159185-A | Method for producing beta-amino alcohol | HOFFMANN LA ROCHE (CH) | 1997-09-10 | — | — | CN | claimed |
| US-6806384-B2 | VIA TREATING N-CARBAMATE-PROTECTED BETA-AMINOEPOXIDE WITH ACID FORMING 5-HYDROXYMETHYL-2-OXAZOLIDINONE, THEN OXIDIZING IN 2,2,6,6-TETRAMETHYL-1-PIPERIDINYLOXY AND HYPOCHLORITE FORMING 4-BENZYL-2-OXO-5-OXAZOLIDINECARBOXYLIC ACID; CRYSTALLIZATION | AJINOMOTO CO., INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| JP-2002371044-A | METHOD FOR MANUFACTURING β-AMINO-α-HYDROXYCARBOXYLIC ACID | AJINOMOTO CO INC | 2002-12-26 | — | — | JP | disclosed |
| US-20020151722-A1 | Production method of beta-amino-alpha-hydroxycarboxylic acid | AJINOMOTO CO. INC (JP) | 2002-10-17 | — | — | US | disclosed |
| EP-0778827-B1 | PROCESS FOR PRODUCING A BETA-AMINO ALCOHOL | DEGUSSA (DE) | 2001-12-12 | — | — | EP | disclosed |
| US-5994555-A | (4S,5S)-4-BENZYL-2-OXO-OXAZOLIDINE-5-CARBOXYLIC ACID FROM PHENYLALANINE AND PHTHALIC ANHYDRIDE | F. HOFFMAN-LAROCHE AG (CH) | 1999-11-30 | — | — | US | disclosed |
| US-5859248-A | Process for the production of a β-amino alcohol | F. HOFFMAN-LA ROCHE AG (CH) | 1999-01-12 | — | — | US | disclosed |
| CN-1159185-A | Method for producing beta-amino alcohol | HOFFMANN LA ROCHE (CH) | 1997-09-10 | — | — | CN | disclosed |
| EP-0778827-A1 | PROCESS FOR PRODUCING A BETA-AMINO ALCOHOL | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996007642-A1 | PROCESS FOR PRODUCING A β-AMINO ALCOHOL | F. HOFFMANN-LA ROCHE AG (DE) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151722-A1 | Production method of beta-amino-alpha-hydroxycarboxylic acid | HAO2, HAAO, DAO | OPRL1 2671/4885CTRB1 2273/4885TSHR 4414/4885 |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | HNMT, PNMT, HRH4 | OPRL1 317/4885CTRB1 4138/4885TSHR 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.